PALIPERIDONE

Clinical safety rating: safe

Animal studies have demonstrated safety

How it works

Paliperidone is an atypical antipsychotic that exerts its effects primarily through antagonism of central dopamine D2 receptors and serotonin 5-HT2A receptors. It also antagonizes alpha-1 and alpha-2 adrenergic receptors, and H1 histaminergic receptors. Paliperidone is the major active metabolite of risperidone.

What the body does with it

Metabolism	Paliperidone is primarily eliminated unchanged via renal excretion. It undergoes limited hepatic metabolism via N-dealkylation and hydroxylation, with CYP2D6 and CYP3A4 partially involved. Approximately 80% of the dose is excreted unchanged in urine.
Excretion	Renal (approximately 80% as unchanged drug and glucuronide conjugate), biliary/fecal (approximately 11%)
Half-life	Approximately 23 hours for the extended-release oral formulation; provides steady trough concentrations with once-daily dosing
Protein binding	74% bound, primarily to albumin and alpha-1-acid glycoprotein
Volume of Distribution	487 L (approximately 7 L/kg for a 70 kg individual); indicates extensive tissue distribution
Bioavailability	Oral (extended-release): 28% relative to immediate-release tablet due to first-pass metabolism; intramuscular: 100% relative to oral solution
Onset of Action	Oral (extended-release): 24–48 hours; intramuscular (monthly): steady state achieved after 4–5 monthly injections
Duration of Action	Oral: 24 hours with once-daily dosing; intramuscular: approximately 4 weeks with monthly injections

Classification & Brands

Dosing & administration

6 mg orally once daily, with dose adjustments in 3 mg increments at intervals of 5 days or more; usual effective range 3-12 mg/day.

Dosage form	TABLET, EXTENDED RELEASE
Renal impairment	For GFR 50-79 mL/min: maximum 6 mg daily; for GFR 10-49 mL/min: 3 mg daily; for GFR <10 mL/min: not recommended.
Liver impairment	No dose adjustment required for mild to moderate (Child-Pugh A or B) hepatic impairment; not studied in severe (Child-Pugh C) impairment.
Pediatric use	Adolescents (12-17 years, ≥51 kg): starting 3 mg once daily, increase by 3 mg every 5+ days up to 6 mg; <51 kg: starting 3 mg once daily, increase by 3 mg every 5+ days up to 3 mg.
Geriatric use	Initiate at 3 mg once daily; increase cautiously in 3 mg increments at intervals of 5 days or more; may require lower maintenance doses due to renal function decline.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Strong CYP3A4 or P-gp inducers may decrease levels Can cause QT prolongation and orthostatic hypotension.

Breastfeeding	Paliperidone is excreted into breast milk; estimated M/P ratio ~0.5. Infant relative dose (RID) ~2.5-5% of maternal weight-adjusted dose. Monitor infant for drowsiness, weight gain, and motor development. Avoid breastfeeding if high maternal dose or infant vulnerability.
Teratogenic Risk	First trimester: Limited human data; animal studies show increased fetal malformations (cleft palate, neural tube defects) at doses ≥ 2.5 mg/kg/day. Second/third trimesters: Risk of extrapyramidal symptoms and withdrawal (agitation, hypertonia, tremors) in neonates after third trimester exposure. Use only if benefit > risk.

Warnings & precautions

■ FDA Black Box Warning

Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Paliperidone is not approved for the treatment of dementia-related psychosis.

Side Effect Profile

Common Effects	Abnormal involuntary movements Dizziness Nystagmus involuntary eye movement Sleepiness Tremors
Serious Effects

Absolute Contraindications

["Hypersensitivity to paliperidone, risperidone, or any excipients"]

Clinical Precautions

Precautions

["Increased mortality in elderly patients with dementia-related psychosis","Cerebrovascular adverse events (including stroke) in elderly dementia patients","Neuroleptic Malignant Syndrome (NMS)","Tardive dyskinesia","Metabolic changes: hyperglycemia, diabetes mellitus, dyslipidemia, weight gain","Hyperprolactinemia","Orthostatic hypotension and syncope","Leukopenia, neutropenia, and agranulocytosis","Seizures","Potential for cognitive and motor impairment","Dysphagia","QT prolongation"]

Clinical Tips & Counseling

Drug interactions

Loading safety data…